Emerging and Fastidious Uropathogens Were Detected by M-PCR with Similar Prevalence and Cell Density in Catheter and Midstream Voided Urine Indicating the Importance of These Microbes in Causing UTIs.

This study compared microbial compositions of midstream and catheter urine specimens from patients with suspected complicated urinary tract infections to determine if emerging and fastidious uropathogens are infecting the bladder or are contaminants. Urine was collected by in-and-out catheter (n = 1000) or midstream voiding (n = 1000) from 2000 adult patients (≥60 years of age) at 17 DispatchHealth sites across 11 states. The two groups were matched by age (mean 81 years), sex (62.1% female, 37.9% male), and ICD-10-CM codes. Microbial detection was performed with multiplex polymerase chain reaction (M-PCR) with a threshold for "positive detection" ≥ 10,000 cells/mL for bacteria or any detection for yeast. Results were divided by sex. In females, 28 of 30 microorganisms/groups were found by both collection methods, while in males 26 of 30 were found by both. There were significant overlaps in the detection and densities of classical uropathogens including In-and-out catheter-collected and midstream voided urine specimens shared significant similarities in microbial detections by M-PCR, with some differences found for a small subset of organisms and between sexes. Non-invasive midstream voided collection of urine specimens for microbial detection and identification in cases of presumed UTI does not result in significantly more contamination compared to in-and-out catheter-collected specimens. Additionally, organisms long regarded as contaminants should be reconsidered as potential uropathogens.

Informations de copyright

© 2023 Wang et al.

Déclaration de conflit d'intérêts

D.B., N.L., E.H., R.A.F., and M.M. are employees of Pathnostics, and D.W. and X.Z. are paid consultants of Pathnostics. L.A.A. reports personal fees from Pathnostics, outside the submitted work. In addition, N.L. has patents (10,160,991, 11,053,532, 17/335,767, 63/493,416, AU2018254514 B2, BR112019021943-9 B1 and NZ 759292) issued to Pathnostics; pending patents (17/178,091 17/880,227 63/503,939) to Pathnostics. D.B. reports patents (US10160991, US11053532, US17178091, US17335767, AU2018254514B2, BR1120190219439B1, NZ759292) issued to PATHNOSTICS; pending patents (US17830227, US18351385, US18351286, US63493416, US63503393, US63514785, PCTUS2216816, PCTUS2277477, EP3612638, JP2022042545, CA3175879, CA3176586, CA3061015, HK620200143373, CN2018800399569, IL294577) to PATHNOSTICS. The authors report no other conflicts of interest in this work.